Low-Dose Tamoxifen in Low-Risk, Early-Stage Breast Cancer

What is the Purpose of this Study?

Hormone receptor-positive breast cancer is the most common type of breast cancer, and 5+ years of hormone therapy is the mainstay of the treatment. However, many patients experience side effects from the medications, and some patients cannot complete the 5 years of treatment. The purpose of this study is to compare the usual hormone therapy medications to low-dose tamoxifen (a type of hormone therapy drug) in women with low-risk, early-stage breast cancer. Researchers aim to learn whether low-dose tamoxifen has the same chance of preventing breast cancer from returning with less side effects, compared to the usual hormonal therapy medications. Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for use in breast cancer. Participants will be assigned to 1 of 2 groups. Group 1 will receive the usual drug used to treat this type of cancer (either regular dose of anastrozole, letrozole, exemestane, or tamoxifen 20 mg/day). Group 2 will receive tamoxifen that is prescribed at a lower dose (10mg every other day).

Eligibility

* Unilateral invasive adenocarcinoma of the breast that is histologically confirmed
* Invasive breast cancer is estrogen receptor positive in ≥ 10% of cells
* HER2 negative by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines

Inclusion Criteria:

* Unilateral invasive adenocarcinoma of the breast that is histologically confirmed
* Invasive breast cancer is estrogen receptor positive in ≥ 10% of cells
* HER2 negative by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
* The patient must have a multigene assay with a low-risk score, including any of the following (if more than one genomic assay was obtained, both are required to be low-risk):
* Oncotype DX recurrence score ≤ 25
* Mamma Print low risk
* Prosigna risk of recurrence ≤ 40
* Tumor size must be ≤ 3 cm by pathologic evaluation
* Adequate surgical removal of all clinically evident disease in the breast with either breast conserving surgery or mastectomy. Negative margins on final pathology are required. Additional excisions may be performed to obtain clear margins before registration
* No clinical (cN1, cN2, cN3) or pathologic (pN1mi, pN1, pN2, or pN3) evidence of lymph node involvement on either needle biopsy or surgical lymph node assessment. Patients with pN0(i+) or pN0 (mol+) are eligible
* Surgical axillary staging (sentinel lymph node biopsy ± axillary lymph node dissection) is completed according to physician discretion
* For patients with negative preoperative axillary ultrasonography, clinicians may selectively choose to forego surgical axillary staging. Ipsilateral axillary ultrasound showing no lymph node involvement with no evidence of lymphadenopathy or suspicious thickening is required in this scenario
* No pathological tumor size \> 3 cm or pT4
* No definitive clinical or radiologic evidence of metastatic disease
* No palpable or radiographically suspicious axillary, supraclavicular, infraclavicular, or internal mammary lymph nodes, unless there is histologic confirmation that these lymph nodes are negative for tumor
* No suspicious microcalcifications, densities, or palpable abnormalities in the ipsilateral or contralateral breast, unless biopsied and found to be benign
* An interval of no more than 20 weeks between the date of surgery and the date of registration
* Must have had a bilateral mammogram or MRI within 6 months prior to registration
* Must be intending to take endocrine therapy for at least 5 years duration
* No prior treatment with endocrine therapy or chemotherapy for the currently diagnosed breast cancer prior to registration. (Short course endocrine therapy of ≤ 6 weeks duration is acceptable after core biopsy and before surgery, if genomic testing is assessed on the biopsy core and meets eligibility requirements for a low-risk score.)
* No use of oral hormone replacement therapy within 7 days prior to registration
* Age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Postmenopausal status confirmed as:
* No spontaneous menses ≥ 1 year
* No menses for \< 1 year with follicle stimulating hormone (FSH) and estradiol levels within a postmenopausal range according to institutional standards
* Previous bilateral surgical oophorectomy
* None of the following conditions:
* Abnormal or dysfunctional uterine bleeding within 1 year prior to study enrollment
* Any patient with known atypia or endometrial pathology that the opinion of the treating investigator would place the patient at undue risk of endometrial cancer with tamoxifen.
* Any patient with a known hypercoagulable state that in the opinion of the treating investigator would put the patient at undue risk of venous thromboembolism with tamoxifen
* No history of breast or thoracic radiotherapy for any previous condition. Patients may complete radiotherapy for the currently diagnosed breast cancer prior to registering for the study. In this scenario, registration must be completed within 12 weeks of completing breast radiotherapy
* No previous history of ipsilateral invasive breast cancer or ipsilateral ductal carcinoma in situ (DCIS), regardless of the disease-free interval
* No synchronous or previous contralateral invasive or non-invasive breast cancer
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* No patients with premenopausal status
* No current treatment with any endocrine therapy for breast cancer prevention or osteoporosis, including raloxifene, tamoxifen, or other selective estrogen receptor modulator. Patients intending to continue oral hormone replacement are not eligible
* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

Show less

Where can I participate?

CS Cancer Tarzana : Nikki Kem-Bernard
CS Cancer at Beverly Hills : Nikki Kem-Bernard
CS Cancer at Cedars-Sinai Medical Center : Nikki Kem-Bernard
Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer

More about this Clinical Trial

What is the full name of this clinical trial?

A012301: LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-risk Early-Stage Breast Cancer Protocol Review Responses

Study Details

Disease Type/Condition

Breast

Principal Investigator

Bitar, Jin Sun

Co-Investigators

Alice Chung, Amin Mirhadi, Andrew Horodner, Ani Balmanoukian, Armando Giuliano, Catherine Dang, David Chan, Dorothy Park, Farin Amersi, Hugo Hool, Johnny Chang, Justin Wayne Tiulim, Maryliza El-Masry, Michele Burnison, Natasha Banerjee, Philomena McAndrew, Ryan Ponec, Scott Karlan, Stephen Shiao, Swati Sikaria, Syed Jilani, Thomas Lowe, Vanessa Dickey, Yuan Yuan

Age Group

Adult

Phase

III

IRB Number

STUDY00004064

ClinicalTrials.gov ID

NCT06671912

Key Eligibility

ClinicalTrials.gov

How do I learn more about this study?

Name

Nikki Kem-Bernard

Nikki.Bernard@cshs.org